Cancer-related research has revealed that GPSM2 could potentially serve as a drug target and prognostic biomarker in hepatocellular carcinoma [47], lung adenocarcinoma [48], and pancreatic cancer [13]. This evidence concerns the gene GPSM2 and lung adenocarcinoma.